Abstract: With new cfDNA NGS assays being able to detect variants from as little as 2-10ng DNA, assay validation to ensure sufficient accuracy has never been so critical. Reference materials that closely mimic real cfDNA samples are essential to support this effort. Here we present results from a comparative study into the production of cfDNA reference standards, assessing enzymatic fragmentation compared to fragmentation by sonication, and the benefit of including a size selection step.Summary: Liquid biopsies hold great promise to revolutionise the field of clinical oncology testing. cfDNA can be extracted from a routine patient blood sample and used to determine the genetic profile of a solid tumour located elsewhere within the body. This facilitates more informative disease management for the clinician, without the need for invasive surgery for the patient.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Diagnostic outcomes of MRE as an investigation for NSS of small bowel disease: Can CTE be a cost-effective alternative in patients above 50 years old?
K ElGendy, E Musgrave, M Twemlow
Appropriateness of MRCP use in a DGH
A Elawad, B Billimoria
Kashtwari D*, Alamoudi. A
Evaluation of the first 18 months of the ‘Abnormal GP Chest X-ray Straight to CT’ Pathway at Princess Alexandra Hospital (Harlow, Essex)
James K. Diss, Tamer Adem, Mark Gregory, Elena Stefan, Vijay Jayaram, Sridhar Redla, Sandra Dimmock
“Incidence of Occult Malignancy Diagnosed in Patients With Unprovoked Pulmonary Embolism”
Dr Fatma Eminaga, Dr Reema Akhter, Dr Sridhar Radla